Full Text
PND23 Cost-effectiveness of Fremanezumab from a Societal Perspective in England

Abstract

Authors

A. Skroumpelos M. Freddi H. Akcicek J.M. Cohen M.T. Driessen

Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×